- Home
- CELC vs CLDT Comparison
CELC vs CLDT Comparison
Compare CELC & CLDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- CLDT
- Stock Information
- Founded
- CELC 2011
- CLDT 2009
- Country
- CELC United States
- CLDT United States
- Employees
- CELC N/A
- CLDT N/A
- Industry
- CELC Medical Specialities
- CLDT Real Estate Investment Trusts
- Sector
- CELC Health Care
- CLDT Real Estate
- Exchange
- CELC Nasdaq
- CLDT Nasdaq
- Market Cap
- CELC 327.3M
- CLDT N/A
- IPO Year
- CELC 2017
- CLDT 2010
- Fundamental
- Price
- CELC $10.53
- CLDT $7.09
- Analyst Decision
- CELC Strong Buy
- CLDT Strong Buy
- Analyst Count
- CELC 6
- CLDT 2
- Target Price
- CELC $30.17
- CLDT $10.75
- AVG Volume (30 Days)
- CELC 195.9K
- CLDT 396.1K
- Earning Date
- CELC 05-14-2025
- CLDT 05-06-2025
- Dividend Yield
- CELC N/A
- CLDT 5.14%
- EPS Growth
- CELC N/A
- CLDT N/A
- EPS
- CELC N/A
- CLDT 0.06
- Revenue
- CELC N/A
- CLDT $316,297,000.00
- Revenue This Year
- CELC N/A
- CLDT N/A
- Revenue Next Year
- CELC N/A
- CLDT $9.88
- P/E Ratio
- CELC N/A
- CLDT $119.98
- Revenue Growth
- CELC N/A
- CLDT 1.79
- 52 Week Low
- CELC $7.58
- CLDT $5.83
- 52 Week High
- CELC $19.77
- CLDT $10.00
- Technical
- Relative Strength Index (RSI)
- CELC 51.41
- CLDT 53.15
- Support Level
- CELC $9.64
- CLDT $6.86
- Resistance Level
- CELC $11.66
- CLDT $7.41
- Average True Range (ATR)
- CELC 0.66
- CLDT 0.20
- MACD
- CELC -0.04
- CLDT 0.05
- Stochastic Oscillator
- CELC 44.06
- CLDT 56.16
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.